Abivax SA (ABVX)
113.39
-0.91
(-0.80%)
USD |
NASDAQ |
Aug 28, 16:00
113.39
0.00 (0.00%)
After-Hours: 20:00
Abivax Enterprise Value : 8.536B for Aug. 27, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 27, 2026 | 8.536B |
| August 26, 2026 | 8.712B |
| August 25, 2026 | 8.824B |
| August 24, 2026 | 8.683B |
| August 21, 2026 | 8.588B |
| August 20, 2026 | 8.845B |
| August 19, 2026 | 9.032B |
| August 18, 2026 | 8.904B |
| August 17, 2026 | 9.046B |
| August 14, 2026 | 8.906B |
| August 13, 2026 | 9.103B |
| August 12, 2026 | 9.426B |
| August 11, 2026 | 9.528B |
| August 10, 2026 | 9.583B |
| August 07, 2026 | 9.855B |
| August 06, 2026 | 9.781B |
| August 05, 2026 | 9.415B |
| August 04, 2026 | 9.400B |
| August 03, 2026 | 9.367B |
| July 31, 2026 | 9.378B |
| July 30, 2026 | 9.331B |
| July 29, 2026 | 8.896B |
| July 28, 2026 | 9.323B |
| July 27, 2026 | 9.622B |
| July 24, 2026 | 9.440B |
| Date | Value |
|---|---|
| July 23, 2026 | 9.873B |
| July 22, 2026 | 9.760B |
| July 21, 2026 | 10.11B |
| July 20, 2026 | 9.900B |
| July 17, 2026 | 10.31B |
| July 16, 2026 | 10.40B |
| July 15, 2026 | 10.33B |
| July 14, 2026 | 10.17B |
| July 13, 2026 | 10.26B |
| July 10, 2026 | 10.57B |
| July 09, 2026 | 10.63B |
| July 08, 2026 | 10.46B |
| July 07, 2026 | 10.75B |
| July 06, 2026 | 10.89B |
| July 02, 2026 | 10.94B |
| July 01, 2026 | 9.984B |
| June 30, 2026 | 10.04B |
| June 29, 2026 | 7.097B |
| June 26, 2026 | 7.204B |
| June 25, 2026 | 6.797B |
| June 24, 2026 | 6.808B |
| June 23, 2026 | 7.278B |
| June 22, 2026 | 7.534B |
| June 18, 2026 | 7.335B |
| June 17, 2026 | 7.414B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Poxel SA | -- |
| OSE Immunotherapeutics SA | -- |
| Cogent Biosciences, Inc. | 5.883B |
| Compass Pathways Plc | 1.608B |
| Vera Therapeutics, Inc. | 2.066B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -56.70M |
| Total Expenses (Quarterly) | 56.70M |
| EPS Diluted (Quarterly) | -0.7181 |
| Earnings Yield | -4.63% |
| Normalized Earnings Yield | -4.083 |